ACTRN12618001692224招募中2 期
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Paroxysmal Atrial Fibrillation and a Cardiac Device
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Participants who:
- •Age between 18-80 years.
- •Paroxysmal (not lasting more than 7 days) atrial fibrillation.
- •An implanted device (loop recorder, pacemaker or defibrillator).
- •An AF burden between 0.1-90% over the past 6 months.
排除标准
- •Participants with:
- •Pregnant or breastfeeding females.
- •Estimated glomerular filtration rate (eGFR) <30ml/min.
- •Liver function tests 3 x ULN due to non-cardiac disease.
- •Have received any investigational research agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of IP.
研究者
相似试验
已完成
2 期
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction.Cardiac remodelling post acute myocardial infarctionCardiovascular - Other cardiovascular diseasesACTRN12615000609550Armaron Bio Pty Ltd147
尚未招募
2 期
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Reducing the Incidence of Atrial Fibrillation in Adults who have undergone Cardiac Surgery.Cardiac bypass graft surgeryvalve surgeryCardiovascular - Other cardiovascular diseasesAtrial FibrillationACTRN12619000658112Armaron Bio Ltd180
进行中（未招募）
不适用
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persistent AsthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaAsthmaEUCTR2010-022279-77-BGGlaxoSmithKline Research & Development Limited132
进行中（未招募）
不适用
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persistent AsthmaAsthmaEUCTR2010-022279-77-DEGlaxoSmithKline Research & Development Limited132
进行中（未招募）
1 期
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural MesotheliomaEUCTR2013-001033-40-GBVerastem Inc400